What is 1910 Genetics?
Founded in 2018 and headquartered in Cambridge, Massachusetts, 1910 Genetics is a biotechnology firm dedicated to identifying and developing therapeutic targets that possess clinical or genetic validation. The company's focus on scientifically validated targets positions it to address unmet medical needs through innovative drug discovery and development.
How much funding has 1910 Genetics raised?
1910 Genetics has raised a total of $47.7M across 2 funding rounds:
Series A
$22M
Stock Offering
$25.7M
Series A (2021): $22M with participation from Playground and M12
Stock Issuance/Offering (2021): $25.7M, investors not publicly disclosed
Key Investors in 1910 Genetics
Playground
Playground is a venture capital firm that likely focuses on investing in innovative technology and life science companies, leveraging its global network to support portfolio growth.
M12
M12, Microsoft's Venture Fund, invests in enterprise software companies primarily in the Series A through C funding stages with a focus on applied AI, business applications, infrastructure, security, and vanguard technologies. As part of its value-add to portfolio companies, M12 offers unique access to strategic go-to-market resources and relationships globally.
What's next for 1910 Genetics?
The substantial enterprise-level funding, including the recent strategic investment, indicates that 1910 Genetics is poised for significant expansion and advancement. This capital infusion will likely fuel further research and development, potentially enabling the company to accelerate its pipeline, scale its operations, and forge new strategic partnerships. The company's trajectory suggests a move towards later-stage development and potential commercialization of its therapeutic candidates.
See full 1910 Genetics company page
